<DOC>
	<DOCNO>NCT02776436</DOCNO>
	<brief_summary>The manufacturer recommend two different regimen prophylactic dexamethasone prevent hypersensitivity fluid retention reaction cause docetaxel : 3-day regime dexamethasone 8mg twice day start day chemotherapy breast cancer prostate cancer 3 time 8mg dexamethasone day docetaxel infusion , give concurrent use prednisone 2dd5mg . There little evidence support high dose regimen use nowadays . There need re-evaluate high dosage dexamethasone three main reason . First , dexamethasone give side effect manifestation latent diabetes mellitus , immunosuppression , personality change , irritability , euphoria , mania mood swing . Second , dexamethasone immune suppressor , might inhibit chemotherapy-induced apoptosis compromise efficacy chemotherapeutic agent . Third , dexamethasone CYP3A4 inducer , might increase docetaxel clearance . This study aim evaluate feasibility reduce prophylactic dexamethasone around docetaxel infusion .</brief_summary>
	<brief_title>Reducing Dexamethasone Around Docetaxel Infusion</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients early breast cancer , advance breast cancer prostate cancer patient receive docetaxel ( minimal 3 cycle monotherapy regimen 4xAC &gt; 4xdocetaxel 3xFEC &gt; 3xdocetaxel 6xTAC ) Age ≥18 year WHO performance status 02 Adequate bone marrow function : white blood cell ( WBCs ) ≥3.0 x 109/l , neutrophil ≥1.5 x 109/l , platelet ≥100 x 109/l Adequate liver function : bilirubin ≤1.5 x upper limit normal ( UNL ) range , ALAT and/or ASAT ≤2.5 x UNL ( &lt; 5 x UNL case liver metastasis ) , Alkaline Phosphatase ≤5 x UNL Adequate renal function : calculated creatinine clearance ≥50 mL/min Survival expectation must &gt; 3 month Written inform consent accord local Ethics Committee requirement Known hypersensitivity docetaxel , paclitaxel chemotherapeutic agent product contain polysorbate 80 early experience anaphylaxis food , insect bite , medication another foreign substance . Existence edema limbs trunk elsewhere localize . Active second malignancy Diabetes Mellitus Serious diseases recent myocardial infarction ( last 6 month ) , clinical sign cardiac failure clinically significant arrhythmias Female patient pregnant breastfeed Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>